Verdinexor (KPT-335) Chemical Properties

Density 

1.49±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

≥44.2 mg/mL in DMSO; insoluble in H2O; ≥2.31 mg/mL in EtOH with ultrasonic

form 

solid

pka

10.04±0.43(Predicted)

CAS DataBase Reference

1392136-43-4

Verdinexor (KPT-335) Usage And Synthesis

Uses

Verdinexor is a potent and selective SINE inhibitor, shown to be effective in treating influenza A virus infection in mice and ferret models.

Biological Activity

verdinexor (kpt-335) is a potent and selective inhibitor of nuclear export [1].nuclear export (sine) is mainly mediated by exportin 1 (xpo1) and mediates specific proteins out of the nucleus, which plays an important role in the regulation of proliferation and the cell cycle [2].verdinexor (kpt-335) is a potent and selective sine inhibitor that acts as an antiviral drug. in a549 cells inoculated with the influenza a and b virus, verdinexor effectively inhibited the replication of the influenza a and b virus strains tested. verdinexor (1 μm) caused the accumulation of vrnps in the nuclei and altered the localization of viral ns1. also, verdinexor increased nuclear negative-sense vrna by 56.6-fold and significantly reduced cytoplasmic negative-sense vrna, which suggested that verdinexor blocked vrnp nuclear export. in 293t cells, verdinexor inhibited xpo1-nep binding [1].in mice infected with influenza virus a, verdinexor significantly reduced lung influenza virus a titers. verdinexor also reduced the expression of proinflammatory cytokines tumor necrosis factor alpha, interleukin-6, interleukin-1β and gamma interferon. in mice infected with a lethal dose, verdinexor inhibited virus penetration of the respiratory tract and virus spread in the lungs [1]. in companion dogs with b- and t-cell lymphomas, verdinexor showed potent cytotoxic activity [2].

storage

Store at -20°C

References

[1]. perwitasari o, johnson s, yan x, et al. verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. j virol, 2014, 88(17): 10228-10243.
[2]. gravina gl, senapedis w, mccauley d, et al. nucleo-cytoplasmic transport as a therapeutic target of cancer. j hematol oncol, 2014, 7: 85.

Verdinexor (KPT-335)(1392136-43-4)Related Product Information

• β-Estradiol
• Lapatinib Ditosylate
• 3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazole
• (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid
• 2-Propenoic acid, 3-iodo-, 1-methylethyl ester, (2Z)-
• (Z)-isopropyl 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate
• PD 173074
• KPT-330, (E)-RN
• (Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3,3-
• KPT-330
• Selumetinib
• Dasatinib
• Gemcitabine
• Phloretin